当前位置: X-MOL 学术Clin. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials
Clinical Cardiology ( IF 2.4 ) Pub Date : 2021-06-15 , DOI: 10.1002/clc.23665
David Z I Cherney 1 , Samuel Dagogo-Jack 2 , Darren K McGuire 3 , Francesco Cosentino 4 , Richard Pratley 5 , Weichung J Shih 6 , Robert Frederich 7 , Mario Maldonado 8 , Jie Liu 9 , Shuai Wang 10 , Christopher P Cannon 11 ,
Affiliation  

A recent meta-analysis of sodium–glucose cotransporter 2 (SGLT2) inhibitor outcome trials reported that SGLT2 inhibitors were associated with reduction in the risk of adverse composite kidney outcomes, with moderate heterogeneity across the trials; however, the endpoints were defined differently across the trials.

中文翻译:

eGFR 持续下降≥40% 的肾脏结局:SGLT2 抑制剂试验的荟萃分析

最近对钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂结局试验的荟萃分析报告称,SGLT2 抑制剂与降低不良复合肾脏结局的风险相关,试验间存在中等异质性;然而,不同试验对终点的定义不同。
更新日期:2021-08-16
down
wechat
bug